VolitionRx Limited (NYSE:VNRX) Director Purchases $99,615.48 in Stock

VolitionRx Limited (NYSE:VNRX) Director Guy Archibald Innes purchased 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the purchase, the director now owns 617,085 shares in the company, valued at approximately $351,738.45. This represents a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

VolitionRx Price Performance

Shares of NYSE:VNRX traded down $0.01 during trading on Tuesday, hitting $0.58. The company had a trading volume of 1,915,668 shares, compared to its average volume of 164,664. The company has a fifty day simple moving average of $0.69 and a two-hundred day simple moving average of $0.67. VolitionRx Limited has a one year low of $0.43 and a one year high of $1.23.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC lifted its position in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VNRX has been the topic of a number of research analyst reports. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com began coverage on shares of VolitionRx in a report on Friday. They issued a “sell” rating for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research note on Tuesday.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.